Aqualung Therapeutics, Corp.

08/08/2024

🌍💧 This World ARDS Day. Aqualung Therapeutics groundbreaking research and innovative therapies are paving the way for new treatments and hope for those affected by Acute Respiratory Distress Syndrome (ARDS). Together, we can support and spread awareness about this critical cause.

01/24/2024

Aqualung Therapeutics is excited to announce that we have been selected as a presenter at the Florida Venture Forum January 31 - February 1st, 2023

10/05/2023

🌬 October is Healthy Lung Month, and we're shedding light on pulmonary hypertension (PH), a serious lung condition. Let's raise awareness about PH, its symptoms, and available treatments to support those affected. Knowledge is power! 💪💙

10/05/2023

🚫 Important Notice: Unauthorized Job Posting Alert 🚫

Hello FaceBook community,

We want to bring to your attention that there is an unauthorized job posting circulating on various platforms claiming to be from Aqualung Therapeutics.

We want to clarify that this is not an official job posting from our company, and we currently do not have any open positions available. If you have been contacted by an individual claiming to be a representative of Aqualung Therapeutics, Corp., regarding a job opportunity, this is a SCAM and please do not give them any personal or banking information.

We kindly request that you refrain from calling or inquiring about this fraudulent position. We apologize for any confusion this may have caused and appreciate your understanding. Please stay tuned to our official channels for any legitimate job opportunities in the future.

Thank you for your cooperation and continued support.

01/11/2023

Aqualung Therapeutics is looking forward to attending the JP Morgan Healthcare and Biotech Showcase Conference in San Francisco on January 9-12. Connect with us and learn more about our lead candidate ALT-100 which is proving to be a solution for not just moderate/severe ARDS patients but also as a potent anti-fibrotic therapy in Radiation Fibrosis.

12/26/2022

12/23/2022

Aqualung Therapeutics is looking forward to attending the JP Morgan Healthcare and Biotech Showcase Conference in San Francisco on January 9-12. Connect with us and learn more about our lead candidate ALT-100 which is proving to be a solution for not just moderate/severe ARDS patients but also as a potent anti-fibrotic therapy in Radiation Fibrosis. Aqualung will be presenting at the Hilton, Franciscan A Ballroom on Tuesday Jan 10th, at 9:45am.

09/21/2022

Arizona Biosciences week is fast approaching. As one of the recipients of the "Fast Lane Award", Aqualung was also featured in the AZ Bio 56 page supplement that was part of the AZ Business Magazine publication. Honored to share our story on how ALT-100 mAb may be a game changer in addressing the vexing condition of ARDS.

This issue of Az Business features the Most Admired Companies in Arizona. To become one of Arizona’s Most Admired Companies, a business needs to excel in leadership, social responsibility, diversity, workplace culture, customer opinion, and innovation.

06/15/2022

It was great to meet with our partner LeaderMed during Bio 2022. LeaderMed have a strong and experienced team ready to initiate ALT-100 mAb into the regulatory process in China and specific Asian markets for the indication of ARDS.

06/15/2022

With the world opening up post Covid, Aqualung had the chance to finally meet FTF with two critical Australian teams that are driving our development of ALT-100mAb...Beyond Drug Development (CRO) who helped with the investigator's brochure and study protocol; and CMAX who will be our P1A Study investigation site. GREAT meetings at Bio 2022 and both of these companies have been superb! Soon the human study begins.....

01/28/2022

We are delighted to be in today's Tucson Star! Tucson startup looks to human trials for drug to treat lung inflammation https://buff.ly/3o3X4V6 via

A $2.5 million investment will help Tucson-based Aqualung Therapeutics launch its first human trials in patients with acute lung inflammation.

01/25/2022

Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer

TUCSON, AZ / ACCESSWIRE / January 25, 2022 / Preclinical prostate cancer (PCa] studies published in the December 17th, 2021 issue of Pharmaceuticals show Aqualung Therapeutic's ALT-100 mAb to significantly improve overall survival and to reduce distal metastases in SCID mice implanted with human pro...